About MiMedx Group (NASDAQ:MDXG)
MiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. The company's proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications; OrthoFlo, an amniotic fluid-derived allograft for homologous applications; Physio, a bone grafting material comprising 100% bone tissue with no added carrier; and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair. The company also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue; AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process; and AmnioFill, a cellular tissue matrix allograft that enhances healing. Its products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. The company sells its products through direct sales force, and independent stocking distributors, and third party representatives in the United States, as well as independent distributors internationally. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MDXG
CUSIPN/A
Phone770-651-9100
Debt
Debt-to-Equity RatioN/A
Current Ratio3.25%
Quick Ratio2.95%
Price-To-Earnings
Trailing P/E Ratio61.92
Forward P/E Ratio32.30
P/E Growth0.97
Sales & Book Value
Annual Sales$245.01 million
Price / Sales3.37
Cash Flow$0.1801 per share
Price / Cash41.26
Book Value$1.21 per share
Price / Book6.14
Profitability
EPS (Most Recent Fiscal Year)$0.12
Net Income$11.97 million
Net Margins11.64%
Return on Equity17.49%
Return on Assets12.69%
Miscellaneous
Employees690
Outstanding Shares111,040,000
MiMedx Group (NASDAQ:MDXG) Frequently Asked Questions
What is MiMedx Group's stock symbol?
MiMedx Group trades on the NASDAQ under the ticker symbol "MDXG."
How will MiMedx Group's stock buyback program work?
MiMedx Group announced that its Board of Directors has authorized a share repurchase plan on Wednesday, December 13th 2017, which authorizes the company to repurchase $10,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's board of directors believes its stock is undervalued.
How were MiMedx Group's earnings last quarter?
MiMedx Group, Inc. (NASDAQ:MDXG) announced its earnings results on Thursday, October, 26th. The medical equipment provider reported $0.08 EPS for the quarter, hitting the Thomson Reuters' consensus estimate of $0.08. The medical equipment provider earned $84.60 million during the quarter, compared to analyst estimates of $84.60 million. MiMedx Group had a return on equity of 17.49% and a net margin of 11.64%. The company's quarterly revenue was up 31.4% on a year-over-year basis. During the same quarter last year, the company posted $0.06 EPS. View MiMedx Group's Earnings History.
What price target have analysts set for MDXG?
5 brokers have issued 1-year target prices for MiMedx Group's shares. Their predictions range from $9.00 to $21.00. On average, they expect MiMedx Group's share price to reach $14.75 in the next twelve months. View Analyst Ratings for MiMedx Group.
What are Wall Street analysts saying about MiMedx Group stock?
Here are some recent quotes from research analysts about MiMedx Group stock:
- 1. Needham & Company LLC analysts commented, "This morning (3/15/18), MDXG issued a press release announcing: 1) management expects 1Q18 revenue to exceed the high end of their guidance range and reiterates their 2018 guidance and 2) the U.S. Department of Justice (DOJ) is reviewing the SEC investigation matters. While MDXG’s business appears to be performing well despite the controversy swirling around the company, we believe investors may continue to heavily discount the fundamentals until more is known about the outcome of the Audit Committee’s investigation, the SEC investigation, and the DOJ review." (3/15/2018)
- 2. According to Zacks Investment Research, "MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Innovations in Regenerative Biomaterials is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant. " (12/8/2017)
Are investors shorting MiMedx Group?
MiMedx Group saw a increase in short interest in April. As of April 13th, there was short interest totalling 49,074,459 shares, an increase of 0.2% from the March 30th total of 49,149,884 shares. Based on an average daily volume of 1,930,423 shares, the days-to-cover ratio is presently 25.4 days. Currently, 47.8% of the company's stock are short sold.
Who are some of MiMedx Group's key competitors?
Some companies that are related to MiMedx Group include NuVasive (NUVA), Nevro (NVRO), Merit Medical Systems (MMSI), NovoCure (NVCR), Mazor Robotics (MZOR), Irhythm Technologies (IRTC), Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), OraSure Technologies (OSUR), Glaukos (GKOS), Luminex (LMNX), K2M Group (KTWO), LeMaitre Vascular (LMAT) and CryoLife (CRY).
Who are MiMedx Group's key executives?
MiMedx Group's management team includes the folowing people:
- Mr. Parker H. Petit, Chairman and Chief Exec. Officer (Age 79)
- Mr. William Charles Taylor, Pres, Chief Operating Officer and Director (Age 50)
- Mr. Michael J. Senken, CFO, Principal Accounting Officer & VP (Age 60)
- Ms. Alexandra O. Haden, Gen. Counsel and Sec. (Age 43)
- Dr. Thomas J. Koob, Chief Scientific Officer (Age 69)
Has MiMedx Group been receiving favorable news coverage?
Headlines about MDXG stock have been trending somewhat positive this week, Accern reports. The research group ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. MiMedx Group earned a news impact score of 0.04 on Accern's scale. They also assigned news coverage about the medical equipment provider an impact score of 46.36 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are MiMedx Group's major shareholders?
MiMedx Group's stock is owned by many different of institutional and retail investors. Top institutional investors include STATE STREET CORP (10.01%). Company insiders that own MiMedx Group stock include Parker H Petit and William Charles Taylor. View Institutional Ownership Trends for MiMedx Group.
How do I buy shares of MiMedx Group?
Shares of MDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MiMedx Group's stock price today?
One share of MDXG stock can currently be purchased for approximately $7.43.
How big of a company is MiMedx Group?
MiMedx Group has a market capitalization of $832.76 million and generates $245.01 million in revenue each year. The medical equipment provider earns $11.97 million in net income (profit) each year or $0.12 on an earnings per share basis. MiMedx Group employs 690 workers across the globe.
How can I contact MiMedx Group?
MiMedx Group's mailing address is 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062. The medical equipment provider can be reached via phone at 770-651-9100 or via email at [email protected]
MarketBeat Community Rating for MiMedx Group (MDXG)
MarketBeat's community ratings are surveys of what our community members think about MiMedx Group and other stocks. Vote "Outperform" if you believe MDXG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDXG will underperform the S&P 500 over the long term. You may vote once every thirty days.
MiMedx Group (NASDAQ:MDXG) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for MiMedx Group in the last 12 months. Their average twelve-month price target is $14.75, suggesting that the stock has a possible upside of 98.52%. The high price target for MDXG is $21.00 and the low price target for MDXG is $9.00. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Buy | Buy |
| Consensus Rating Score: | 2.20 | 2.20 | 2.50 | 2.50 |
| Ratings Breakdown: | 1 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s) |
| Consensus Price Target: | $14.75 | $14.75 | $17.00 | $14.8333 |
| Price Target Upside: | 98.52% upside | 107.45% upside | 41.78% upside | 10.26% downside |
MiMedx Group (NASDAQ:MDXG) Consensus Price Target History
MiMedx Group (NASDAQ:MDXG) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
MiMedx Group (NASDAQ:MDXG) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
MiMedx Group (NASDAQ MDXG) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 12.40%
Institutional Ownership Percentage: 79.79%
MiMedx Group (NASDAQ MDXG) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 6/14/2017 | William Charles Taylor | Insider | Sell | 80,000 | $14.52 | $1,161,600.00 | 547,424 |  |
| 5/25/2017 | William Charles Taylor | Insider | Sell | 26,571 | $13.74 | $365,085.54 | 533,612 | |
| 4/27/2017 | William Charles Taylor | Insider | Sell | 26,000 | $11.40 | $296,400.00 | 540,460 | |
| 9/6/2016 | William Charles Taylor | Insider | Sell | 20,400 | $7.55 | $154,020.00 | 566,566 | |
| 8/1/2016 | William Charles Taylor | Insider | Sell | 29,112 | $7.55 | $219,795.60 | 612,316 | |
| 6/16/2016 | William Charles Taylor | COO | Sell | 24,333 | $7.52 | $182,984.16 | 616,078 | |
| 5/20/2016 | Parker H Petit | CEO | Buy | 20,000 | $6.99 | $139,800.00 | 5,009,121 | |
| 5/17/2016 | Parker H Petit | CEO | Buy | 30,000 | $6.82 | $204,600.00 | 4,989,121 | |
| 5/13/2016 | Parker H Petit | CEO | Buy | 40,000 | $6.75 | $270,000.00 | 4,959,121 | |
| 5/12/2016 | Parker H Petit | CEO | Buy | 50,000 | $6.74 | $337,000.00 | 4,919,121 | |
| 11/13/2015 | Charles Robert Evans | Director | Buy | 10,000 | $7.84 | $78,400.00 | 31,878 | |
| 11/10/2015 | Parker H Petit | CEO | Buy | 131,925 | $7.58 | $999,991.50 | 5,026,821 | |
| 10/30/2015 | Alexandra O. Haden | General Counsel | Buy | 4,150 | $7.92 | $32,868.00 | 40,528 | |
| 5/28/2015 | Larry W Papasan | Director | Sell | 5,958 | $10.09 | $60,116.22 | | |
| 5/18/2015 | William Charles Taylor | COO | Sell | 150,000 | $10.01 | $1,501,500.00 | | |
| 10/31/2014 | William Charles Taylor | COO | Sell | 150,000 | $10.01 | $1,501,500.00 | | |
| 7/1/2014 | William Charles Taylor | COO | Sell | 150,000 | $7.50 | $1,125,000.00 | | |
| 1/17/2014 | Parker Petit | CEO | Sell | 150,000 | $8.28 | $1,242,000.00 | | |
| 8/28/2013 | William Charles Taylor | COO | Sell | 9,800 | $6.15 | $60,270.00 | | |
| 8/7/2013 | William Charles Taylor | COO | Sell | 183,765 | $6.21 | $1,141,180.65 | | |
| 5/16/2013 | Steve Gorlin | Director | Sell | 30,000 | $6.46 | $193,800.00 | | |
(Data available from 1/1/2013 forward)
MiMedx Group (NASDAQ MDXG) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against MiMedx Group Inc. and Reminds Investors With Losses to Contact The Firm
finance.yahoo.com - April 24 at 5:23 PM |
| Lifshitz & Miller LLP Announces Investigation of Cancer Genetics, Inc., Colony Northstar, Inc., Pacific Commerce Bancorp, MiMedx Group, Inc., Sorrento Therapeutics, Inc., TrueCar, Inc., and Windstream Holdings, Inc.
finance.yahoo.com - April 24 at 5:23 PM |
| DEADLINE TOMORROW: The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of MiMedx Group Inc. Shareholders and a Lead Plaintiff Deadline of April 25, 2018
finance.yahoo.com - April 24 at 5:23 PM |
| FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $100K of Class Action Against MiMedx Group, Inc. (MDXG) & Lead Plaintiff Deadline: April 25, 2018
finance.yahoo.com - April 24 at 5:23 PM |
| DEADLINE UPCOMING: Levi & Korsinsky, LLP Reminds Shareholders of MiMedx Group Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 25, 2018 – MDXG
finance.yahoo.com - April 24 at 8:35 AM |
| MiMedx Will Host Its First Quarter Shareholder Conference Call On Thursday, April 26, 2018
finance.yahoo.com - April 23 at 5:02 PM |
| MiMedx to Highlight Efficacy of Its Allografts in Presentations at SAWC Spring Conference
finance.yahoo.com - April 23 at 5:02 PM |
| 2-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against MiMedx Group Inc. and Reminds Investors With Losses to Contact The Firm
finance.yahoo.com - April 23 at 5:02 PM |
 | MIMEDX 5 DAY DEADLINE ALERT: Approximately 5 Days Remain; Former Louisiana Attorney General and Kahn ...
www.businesswire.com - April 22 at 6:19 PM |
| Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against MiMedx Group ...
www.businesswire.com - April 22 at 6:19 PM |
| MIMEDX 5 DAY DEADLINE ALERT: Approximately 5 Days Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit ...
www.businesswire.com - April 21 at 8:33 AM |
| MIMEDX 5 DAY DEADLINE ALERT: Approximately 5 Days Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against MiMedx Group Inc. - MDXG
finance.yahoo.com - April 21 at 8:33 AM |
| Bragar Eagel & Squire, PC Reminds Investors That a Class Action Lawsuit Has Been Filed Against MiMedx Group, Inc ...
www.businesswire.com - April 20 at 5:09 PM |
| Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action ...
www.businesswire.com - April 19 at 5:23 PM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of MiMedx Group Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 25, 2018 – MDXG
finance.yahoo.com - April 19 at 5:23 PM |
| Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against MiMedx Group Inc. (MDXG)
finance.yahoo.com - April 19 at 8:33 AM |
| MDXG INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving MiMedx Group Inc. and a Lead Plaintiff Deadline of April 25, 2018
finance.yahoo.com - April 18 at 5:31 PM |
 | MiMedx Group, Inc. (MDXG) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 18 at 11:30 AM |
| FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In MiMedx Group, Inc. (Nasdaq: MDXG) To Contact The Firm
finance.yahoo.com - April 18 at 8:33 AM |
| Investors Buy High Volume of MiMedx Group Put Options (MDXG)
www.americanbankingnews.com - April 18 at 7:04 AM |
| IMPORTANT DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against MiMedx Group Inc. and Reminds Investors With Losses to Contact The Firm
finance.yahoo.com - April 17 at 8:54 AM |
| The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of MiMedx Group Inc. Shareholders and a Lead Plaintiff Deadline of April 25, 2018
finance.yahoo.com - April 16 at 5:08 PM |
| DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against MiMedx Group Inc. and Reminds Investors With Losses to Contact The Firm
finance.yahoo.com - April 14 at 4:59 PM |
 | MIMEDX SHAREHOLDER ALERT: CLAIMSFILER REMINDS...
www.benzinga.com - April 14 at 8:42 AM |
 | Global Advanced Wound Care Market Opportunities 2018: MiMedx Group, 3 M Company, Medtronic , Kinetic Concepts, Integra Life Sciences
www.marketwatch.com - April 13 at 8:43 AM |
| EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of MiMedx Group Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 25, 2018
finance.yahoo.com - April 12 at 5:20 PM |
| MDXG SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving MiMedx Group Inc. and a Lead Plaintiff Deadline of April 25, 2018
finance.yahoo.com - April 12 at 5:20 PM |
| MiMedx Group, Inc. (MDXG) Short Interest Update
www.americanbankingnews.com - April 12 at 2:17 AM |
| Safirstein Metcalf LLP Reminds Investors that Class Actions have been Filed Against MiMedx Group, Inc. – MDXG
feeds.benzinga.com - April 11 at 7:10 PM |
| MiMedx Group (MDXG) Upgraded at BidaskClub
www.americanbankingnews.com - April 10 at 9:26 PM |
| DEADLINE APPROACHING: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against MiMedx Group Inc. and Reminds Investors With Losses to Contact The Firm
finance.yahoo.com - April 10 at 5:16 PM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of MiMedx Group Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 25, 2018 – MDXG
finance.yahoo.com - April 9 at 5:07 PM |
 | Hagens Berman Reminds MiMedx Group Investors of the April 25, 2018 Lead Plaintiff Deadline in the Pending ...
www.globenewswire.com - April 8 at 9:48 AM |
| Zacks Investment Research Lowers MiMedx Group (MDXG) to Sell
www.americanbankingnews.com - April 7 at 7:17 PM |
| APRIL 25 DEADLINE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against MiMedx Group Inc. And Reminds Investors With Losses To Contact The Firm
finance.yahoo.com - April 7 at 4:18 PM |
| Hagens Berman Reminds MiMedx Group Investors of the April 25, 2018 Lead Plaintiff Deadline in the Pending Securities Class Action
finance.yahoo.com - April 6 at 5:25 PM |
| SHARHOLDER ALERT: Block & Leviton LLP Announces It Has Filed A Class Action Against MiMedx Group, Inc. (MDXG)
finance.yahoo.com - April 6 at 5:25 PM |
| MiMedx Group (MDXG) Receives Buy Rating from Needham & Company LLC
www.americanbankingnews.com - April 4 at 12:34 AM |
| MiMedx Group (MDXG) and Cardiovascular Systems (CSII) Financial Comparison
www.americanbankingnews.com - April 3 at 11:38 PM |
| EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of MiMedx Group Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 25, 2018 - MDXG
finance.yahoo.com - April 2 at 5:13 PM |
| MDXG INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf ...
www.businesswire.com - March 30 at 5:16 PM |
 | MiMedx Enrolls First Patient In Its Phase 2B Clinical Trial Of RMAT Designated AmnioFix® Injectable For The ...
www.prnewswire.com - March 30 at 5:16 PM |
| MDXG INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of MiMedx Group Inc. Investors
finance.yahoo.com - March 30 at 5:16 PM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of MiMedx Group Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 25, 2018 - MDXG
finance.yahoo.com - March 29 at 5:15 PM |
| MiMedx Enrolls First Patient In Its Phase 2B Clinical Trial Of RMAT Designated AmnioFix® Injectable For The Treatment Of Osteoarthritis Of The Knee
finance.yahoo.com - March 28 at 8:47 AM |
| MiMedx Group, Inc. (MDXG) Short Interest Up 11.0% in March
www.americanbankingnews.com - March 28 at 1:40 AM |
| EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of MiMedx Group Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 25, 2018 – MDXG
finance.yahoo.com - March 27 at 8:48 AM |
 | Are Options Traders Betting on a Big Move in MiMedx Group (MDXG) Stock?
www.msn.com - March 26 at 5:04 PM |
 | MiMedx's AmnioFix shows positive effect in mid-stage study in plantar fasciitis; shares ahead 4%
seekingalpha.com - March 26 at 5:04 PM |
| SHAREHOLDER ALERT: Spector, Roseman & Kodroff, P.C. Announces Class Action Lawsuit Filed Against MiMedx Group, Inc.
finance.yahoo.com - March 26 at 5:04 PM |
MiMedx Group (NASDAQ:MDXG) SEC Filings
This page is loading this company's SEC Filings. Please wait...
MiMedx Group (NASDAQ:MDXG) Income Statement, Balance Sheet and Cash Flow Statement
MiMedx Group (NASDAQ MDXG) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
